CollabRx to Present at 5th Annual LD MICRO Conference
SAN FRANCISCO -- December 03, 2012
CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on genomics,
today announced that it is scheduled to present at LD MICRO’s 5^th Annual
Conference on Thursday, December 6, 2013, at 10 a.m. Pacific Standard Time.
The December 5-6 conference is to be held at the Luxe Sunset Bel Air Hotel at
11461 Sunset Boulevard in Los Angeles, CA.
CollabRx Chairman and Co-CEO Thomas R. Mika will be presenting to investors
and available for one-on-one meetings during the conference.
CollabRx uses cloud-based expert systems to inform healthcare decision-making
by aggregating and contextualizing the world’s knowledge on molecular medicine
with specific insights from the nation’s top clinical experts. The company
combines proprietary content and technology to provide clinically relevant and
dynamically updated knowledge on clinical trials, drugs, biologics and other
information relevant for cancer treatment planning. This knowledge is
supported by CollabRx’s large and growing network of over 50 leading clinical
practitioners in the United States. While CollabRx and its advisors do not
provide specific treatment recommendations, this clinically relevant knowledge
is a key part of the “context engine” for informing healthcare
About LD MICRO
LD MICRO is a by-invitation-only newsletter firm that focuses on finding
undervalued companies in the micro-cap space. Since 2002, the firm has
published an annual list of recommended stocks, as well as comprehensive
reports on select companies throughout the year. The firm also hosts the LD
MICRO Micro-Cap Growth Conference for institutional investors in December of
each year. LD MICRO concentrates on finding, researching and investing in
companies that are overlooked by most institutional investors. It is a
non-registered investment advisor. For more information, please contact
408-457-1042 or visit www.ldmicro.com.
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert
systems to inform health care decision-making. CollabRx uses information
technology to aggregate and contextualize the world’s knowledge on
genomics-based medicine with specific insights from the nation’s top cancer
experts starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at http://www.collabrx.com.
James M. Karis, Co-CEO, 415-248-5350
Thomas R. Mika, Co-CEO, 415-248-5350
Robert Ferri Partners, LLC
Robert Ferri, 415-575-1589 (direct)
Press spacebar to pause and continue. Press esc to stop.